ArticleParasites & vectors2026
Efficacy of Revolution
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBorrelia burgdorferi and Anaplasma phagocytophilum are transmitted by Ixodes spp., with antibodies having been detected in cats in endemic areas. The combination of selamectin plus sarolaner (Revolution
methodsTen cats per group were treated once topically either with placebo solution (0.1 ml/kg) or with the minimum label dose of RP (6.0 mg/kg selamectin plus 1.0 mg/kg sarolaner). Thirty days post-treatment, cats were infested with 50 wild-caught adult I. scapularis. Ticks were counted, categorized, and removed on day 35. Blood collections for serology occurred on days -6, 30 (prior to infestation), 49, 63, 77, 91, and 104. Serum antibody assay results (B. burgdorferi and A. phagocytophilum) and polymerase chain reaction (PCR) of skin biopsies (B. burgdorferi) were used to define infection rates in the cats.
resultsTreatment with RP resulted in a 100% reduction of I. scapularis ticks compared with placebo-treated cats. In placebo-treated cats, antibodies against B. burgdorferi, A. phagocytophilum, both agents, and B. burgdorferi DNA in skin (five, nine, six, and three cats, respectively) were detected by day 104. In contrast, none of the RP-treated cats developed B. burgdorferi antibodies or DNA in skin biopsies, and A. phagocytophilum antibodies were detected in only two cats, significantly lower than in placebo-treated cats.
conclusionsResults suggest that a single application of RP at the minimum label dose reduces the risk of infection by both B. burgdorferi and A. phagocytophilum, when infected at the end of the dosing interval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.